Nikki Kit
Product Images NDC 68180-886

12 FDA label images from Lupin Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Nikki (NDC 68180-886). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lupin Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig-1 (D5033102 E177 4057 Bf0d D7df320d59e9 01)

Fig-1 (D5033102 E177 4057 Bf0d D7df320d59e9 01)
A forest plot chart illustrating comparative hazard, rate, and odds ratios from various studies grouped by study type: prospective cohort, retrospective cohort, case-control, and non-fetal idiopathic cases. The horizontal axis uses a logarithmic scale ranging from 0.1 to 10, with each study's effect size represented as a diamond and confidence intervals shown with horizontal lines.*
FDA Label Image

Fig-2 (D5033102 E177 4057 Bf0d D7df320d59e9 02)

Fig-2 (D5033102 E177 4057 Bf0d D7df320d59e9 02)
A horizontal bar chart comparing the number of women with a blood clot per 10,000 women years across four categories: Non-Pregnant Non-COC users (range 1 to 5), COC-users (range 3 to 9), Pregnancy (range 5 to 20), and Postpartum (12 weeks only) with the highest range from 40 to 65. A footnote explains pregnancy data are based on actual duration from reference studies, with a modeled rate of 7 to 27 per 10,000 women years assuming nine months duration.*
FDA Label Image

1 (D5033102 E177 4057 Bf0d D7df320d59e9 03)

1 (D5033102 E177 4057 Bf0d D7df320d59e9 03)
A forest plot illustrating the effect estimates comparing 'Ever COC vs. Never COC Use' and 'Current COC use vs. Never-Use' from various studies. The horizontal axis shows effect estimates ranging approximately from -1.50 to 2.00. Several studies with confidence intervals are plotted along with odds ratios (OR), relative risks (RR), and hazard ratios (HR) with their confidence intervals on the right.*
FDA Label Image

Fig-3 (D5033102 E177 4057 Bf0d D7df320d59e9 04)

Fig-3 (D5033102 E177 4057 Bf0d D7df320d59e9 04)
Chemical structure diagrams of the active ingredients Drospirenone and Ethinyl estradiol as labeled, associated with the pharmaceutical product Nikki by Lupin Pharmaceuticals, Inc.*
FDA Label Image

Fig (D5033102 E177 4057 Bf0d D7df320d59e9 05)

FDA Label Image

Fig-4 (D5033102 E177 4057 Bf0d D7df320d59e9 06)

Fig-4 (D5033102 E177 4057 Bf0d D7df320d59e9 06)
A vertical effectiveness chart ranking birth control methods by pregnancies per 100 women per year. From top (most effective) to bottom (least effective): implants, injections, intrauterine devices, sterilization; birth control pills, skin patch, vaginal ring with hormones; condoms, diaphragm; abstinence during fertile days, spermicide, withdrawal; and no birth control resulting in most pregnancies.*
FDA Label Image

Fig-5 (D5033102 E177 4057 Bf0d D7df320d59e9 07)

Fig-5 (D5033102 E177 4057 Bf0d D7df320d59e9 07)
A weekly calendar-style pill reminder diagram showing four rows labeled Week 2, Week 3, and Week 4 and columns for each day of the week from Sunday to Saturday. Circles representing pill slots are arranged in a grid with arrows indicating the daily sequence to take the medication. The diagram includes a notation "Start Here" pointing to the first pill slot on Week 2 Sunday.*
FDA Label Image

Fig-6 (D5033102 E177 4057 Bf0d D7df320d59e9 08)

Fig-6 (D5033102 E177 4057 Bf0d D7df320d59e9 08)
A horizontal bar chart illustrating the range of the number of women experiencing blood clots per 10,000 women years (WY) across four categories: Non-Pregnant Non-COC users (1 to 5), COC users (3 to 9), Pregnancy (5 to 20), and Postpartum (12 weeks only) with the highest range (40 to 65). Pregnancy data includes a note on the duration assumption used in reference studies.*
FDA Label Image

Image (D5033102 E177 4057 Bf0d D7df320d59e9 09)

FDA Label Image

Blister (D5033102 E177 4057 Bf0d D7df320d59e9 10)

Blister (D5033102 E177 4057 Bf0d D7df320d59e9 10)
The image shows the lidding foil label for Nikki (drospirenone and ethinyl estradiol tablets USP) with a strength of 3 mg/0.02 mg. The label includes storage instructions to keep at 25°C with permitted excursions, distributor Lupin Pharmaceuticals, Inc. in Naples, FL, and manufacturer Lupin Limited in India. The label also features a barcode, the product's NDC 68180-886-71, and a monthly self breast exam reminder.*
FDA Label Image

Pouch (D5033102 E177 4057 Bf0d D7df320d59e9 11)

Pouch (D5033102 E177 4057 Bf0d D7df320d59e9 11)
Packaging label for Nikki tablets USP by Lupin Pharmaceuticals, Inc. The label specifies drospirenone and ethinyl estradiol with strengths of 3 mg/0.02 mg. The package contains 1 blister of 28 tablets. The label includes warnings, storage instructions, and a barcode, with a note stating the product is for prescription use only.*
FDA Label Image

Carton Label (D5033102 E177 4057 Bf0d D7df320d59e9 12)

Carton Label (D5033102 E177 4057 Bf0d D7df320d59e9 12)
Nikki 3 mg/0.02 mg tablets packaging label by Lupin Pharmaceuticals, Inc. The product contains drospirenone and ethinyl estradiol tablets USP. It is distributed by Lupin Pharmaceuticals, Inc., Naples, FL, and manufactured by Lupin Limited in India. The label shows NDC 68180-886-73 and packaging for 3 blisters of 28 tablets each. The label includes standard product warnings and usage instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.